Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert G Ridley

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Microbes and Infection|March 7, 2002
Introduction. Antimalarial drug resistance: ramifications, explanations and challengesRobert G Ridley
EMBO Reports|June 6, 2003
Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experiences with public-private partnershipsRobert G Ridley
The Lancet. Infectious Diseases|March 15, 2002
Robert G Ridley--realising the potential of public-private partnerships. Interview by Pam DasRobert G Ridley
Nature|August 22, 2003
Malaria: to kill a parasiteRobert G Ridley
Nature|February 8, 2002
Medical need, scientific opportunity and the drive for antimalarial drugsRobert G Ridley
Nature Medicine|December 4, 2004
Research on infectious diseases requires better coordinationRobert G Ridley
Proceedings of the National Academy of Sciences of the United States of America|October 11, 2002
Chemotherapeutic hope on the horizon for Plasmodium vivax malaria?Robert G Ridley
Nature Reviews. Drug Discovery|December 12, 2003
Virtual drug discovery and development for neglected diseases through public-private partnershipsSolomon Nwaka, Robert G Ridley
Nature Reviews. Microbiology|April 14, 2004
A knowledgeable partnershipRobert G Ridley, David O'Connell
Expert Opinion on Drug Discovery|March 16, 2013
Helminth drug initiativeRobert G Ridley, Kiyoshi Kita
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Microbes and Infection|March 7, 2002
Introduction. Antimalarial drug resistance: ramifications, explanations and challengesRobert G Ridley
EMBO Reports|June 6, 2003
Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experiences with public-private partnershipsRobert G Ridley
The Lancet. Infectious Diseases|March 15, 2002
Robert G Ridley--realising the potential of public-private partnerships. Interview by Pam DasRobert G Ridley
Nature|August 22, 2003
Malaria: to kill a parasiteRobert G Ridley
Nature|February 8, 2002
Medical need, scientific opportunity and the drive for antimalarial drugsRobert G Ridley
Nature Medicine|December 4, 2004
Research on infectious diseases requires better coordinationRobert G Ridley
Proceedings of the National Academy of Sciences of the United States of America|October 11, 2002
Chemotherapeutic hope on the horizon for Plasmodium vivax malaria?Robert G Ridley
Nature Reviews. Drug Discovery|December 12, 2003
Virtual drug discovery and development for neglected diseases through public-private partnershipsSolomon Nwaka, Robert G Ridley
Nature Reviews. Microbiology|April 14, 2004
A knowledgeable partnershipRobert G Ridley, David O'Connell
Expert Opinion on Drug Discovery|March 16, 2013
Helminth drug initiativeRobert G Ridley, Kiyoshi Kita
Pageof 2